Galit Alter | |
|---|---|
| Born | 1976 or 1977 (age 46–47) [2] |
| Education | Ph.D. from McGill University [3] |
| Awards | MGH Research Scholars Award (twice) [1] |
| Scientific career | |
| Fields | immunology, infectious diseases |
| Institutions |
Harvard Medical School Ragon Institute |
| Website |
ragoninstitute |
Galit Alter is an immunologist and virologist, professor of medicine at Harvard Medical School, and group leader at the Ragon Institute of MGH, MIT and Harvard. She is known for her work on the expansion of particular natural killer cell subtypes in response to HIV-1 infection. [4] [5] She has also contributed to the understanding of how SARS-CoV-2 antibody titers correlate with sustained humoral protection, including identifying coordinated immune cell-antibody signatures that may predict COVID-19 infection outcome. [2] [6]
In October 2022 she became Vice President of Immunology in Infectious Disease Research at Moderna [7]
- ^ "Alter - Ragon Institute of MGH, MIT and Harvard". ragoninstitute.org. Retrieved 2021-02-23.
- ^ a b Scanlon, Jessie (2020-12-10). "Galit Alter: Connecting scientists to speed up the COVID-19 fight". bostonglobe.com. Retrieved 2021-02-23.
- ^ "Virology Faculty Member - Galit Alter". hms.harvard.edu. Retrieved 2021-02-23.
- ^ Alter, Galit; Malenfant, Jessica M; Altfeld, Marcus (2004). "CD107a as a functional marker for the identification of natural killer cell activity". J Immunol Methods. 294 (1–2): 15–22. doi: 10.1016/j.jim.2004.08.008. PMID 15604012. Retrieved 1 April 2021.
- ^ Alter, Galit; Martin, Maureen P; et al. (26 Nov 2007). "Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes". J Exp Med. 204 (12): 3027–36. doi: 10.1084/jem.20070695. PMC 2118524. PMID 18025129.
- ^ Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer...; Alter, Galit (15 September 2020). "Distinct Early Serological Signatures Track with SARS-CoV-2 Survival". Immunity. 53 (3): 524–532. doi: 10.1016/j.immuni.2020.07.020. PMC 7392190. PMID 32783920.
- ^ "Personal LinkedIn page of Dr. Galit Alter".
| International | |
|---|---|
| National | |
| Academics | |
 | This biographical article about a scientist is a stub. You can help Wikipedia by expanding it. |
Galit Alter | |
|---|---|
| Born | 1976 or 1977 (age 46–47) [2] |
| Education | Ph.D. from McGill University [3] |
| Awards | MGH Research Scholars Award (twice) [1] |
| Scientific career | |
| Fields | immunology, infectious diseases |
| Institutions |
Harvard Medical School Ragon Institute |
| Website |
ragoninstitute |
Galit Alter is an immunologist and virologist, professor of medicine at Harvard Medical School, and group leader at the Ragon Institute of MGH, MIT and Harvard. She is known for her work on the expansion of particular natural killer cell subtypes in response to HIV-1 infection. [4] [5] She has also contributed to the understanding of how SARS-CoV-2 antibody titers correlate with sustained humoral protection, including identifying coordinated immune cell-antibody signatures that may predict COVID-19 infection outcome. [2] [6]
In October 2022 she became Vice President of Immunology in Infectious Disease Research at Moderna [7]
- ^ "Alter - Ragon Institute of MGH, MIT and Harvard". ragoninstitute.org. Retrieved 2021-02-23.
- ^ a b Scanlon, Jessie (2020-12-10). "Galit Alter: Connecting scientists to speed up the COVID-19 fight". bostonglobe.com. Retrieved 2021-02-23.
- ^ "Virology Faculty Member - Galit Alter". hms.harvard.edu. Retrieved 2021-02-23.
- ^ Alter, Galit; Malenfant, Jessica M; Altfeld, Marcus (2004). "CD107a as a functional marker for the identification of natural killer cell activity". J Immunol Methods. 294 (1–2): 15–22. doi: 10.1016/j.jim.2004.08.008. PMID 15604012. Retrieved 1 April 2021.
- ^ Alter, Galit; Martin, Maureen P; et al. (26 Nov 2007). "Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes". J Exp Med. 204 (12): 3027–36. doi: 10.1084/jem.20070695. PMC 2118524. PMID 18025129.
- ^ Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer...; Alter, Galit (15 September 2020). "Distinct Early Serological Signatures Track with SARS-CoV-2 Survival". Immunity. 53 (3): 524–532. doi: 10.1016/j.immuni.2020.07.020. PMC 7392190. PMID 32783920.
- ^ "Personal LinkedIn page of Dr. Galit Alter".
| International | |
|---|---|
| National | |
| Academics | |
|
| This biographical article about a scientist is a stub. You can help Wikipedia by expanding it. |